Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA)

Abstract Introduction Filgotinib is an oral Janus kinase 1 (JAK1) preferential inhibitor approved for adult patients with moderate-to-severe active rheumatoid arthritis (RA) who have responded inadequately to, or who are intolerant of, one or more disease-modifying antirheumatic drugs (DMARDs). Whil...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Georg Pongratz, Rieke Alten, Torsten Witte, Christine Pausch, Robert Reinhold, David Pittrow, Gerd R. Burmester
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Adis, Springer Healthcare 2026-01-01
Serie:	Rheumatology and Therapy
Soggetti:	Filgotinib Pain Patient-reported outcomes Real-world evidence JAK inhibitors RAID score
Accesso online:	https://doi.org/10.1007/s40744-025-00814-1
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!